180 related articles for article (PubMed ID: 18990367)
1. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction.
Cerrillo M; Rodríguez S; Mayoral M; Pacheco A; Martínez-Salazar J; Garcia-Velasco JA
Fertil Steril; 2009 Apr; 91(4 Suppl):1526-8. PubMed ID: 18990367
[TBL] [Abstract][Full Text] [Related]
2. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
3. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
[TBL] [Abstract][Full Text] [Related]
4. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.
Griesinger G; von Otte S; Schroer A; Ludwig AK; Diedrich K; Al-Hasani S; Schultze-Mosgau A
Hum Reprod; 2007 May; 22(5):1348-52. PubMed ID: 17303632
[TBL] [Abstract][Full Text] [Related]
5. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome.
Cerrillo M; Pacheco A; Rodríguez S; Gómez R; Delgado F; Pellicer A; Garcia-Velasco JA
Fertil Steril; 2011 Jun; 95(8):2517-9. PubMed ID: 21269615
[TBL] [Abstract][Full Text] [Related]
6. Prolonged HCG action affects angiogenic substances and improves follicular maturation, oocyte quality and fertilization competence in patients with polycystic ovarian syndrome.
Bokal EV; Vrtovec HM; Virant Klun I; Verdenik I
Hum Reprod; 2005 Jun; 20(6):1562-8. PubMed ID: 15734758
[TBL] [Abstract][Full Text] [Related]
7. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles.
Hernández ER; Gómez-Palomares JL; Ricciarelli E
Fertil Steril; 2009 Apr; 91(4 Suppl):1358-61. PubMed ID: 18555236
[TBL] [Abstract][Full Text] [Related]
8. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome.
Pau E; Alonso-Muriel I; Gómez R; Novella E; Ruiz A; García-Velasco JA; Simón C; Pellicer A
Hum Reprod; 2006 Jun; 21(6):1453-60. PubMed ID: 16488907
[TBL] [Abstract][Full Text] [Related]
10. Failure of triggering oocyte maturation with a GnRH agonist in polycystic ovary syndrome: two case reports.
Honnma H; Hashiba Y; Asada Y; Endo T
Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):239-40. PubMed ID: 21477915
[No Abstract] [Full Text] [Related]
11. The effects of 'coasting' on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome.
Tozer AJ; Iles RK; Iammarrone E; Gillott CM; Al-Shawaf T; Grudzinskas JG
Hum Reprod; 2004 Mar; 19(3):522-8. PubMed ID: 14998945
[TBL] [Abstract][Full Text] [Related]
12. Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome.
Herrero L; Pareja S; Losada C; Cobo AC; Pellicer A; Garcia-Velasco JA
Fertil Steril; 2011 Mar; 95(3):1137-40. PubMed ID: 21047635
[TBL] [Abstract][Full Text] [Related]
13. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial.
Galindo A; Bodri D; Guillén JJ; Colodrón M; Vernaeve V; Coll O
Gynecol Endocrinol; 2009 Jan; 25(1):60-6. PubMed ID: 19165664
[TBL] [Abstract][Full Text] [Related]
14. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
[TBL] [Abstract][Full Text] [Related]
15. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.
Griesinger G; Kolibianakis EM; Papanikolaou EG; Diedrich K; Van Steirteghem A; Devroey P; Ejdrup Bredkjaer H; Humaidan P
Fertil Steril; 2007 Sep; 88(3):616-21. PubMed ID: 17451691
[TBL] [Abstract][Full Text] [Related]
16. Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin.
Humaidan P; Westergaard LG; Mikkelsen AL; Fukuda M; Yding Andersen C
Fertil Steril; 2011 May; 95(6):2034-8. PubMed ID: 21377153
[TBL] [Abstract][Full Text] [Related]
17. Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome.
Şükür YE; Özmen B; Özdemir ED; Seval MM; Kalafat E; Sönmezer M; Berker B; Aytaç R; Atabekoğlu CS
Reprod Biomed Online; 2017 Jan; 34(1):5-10. PubMed ID: 27771155
[TBL] [Abstract][Full Text] [Related]
18. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.
Melo M; Busso CE; Bellver J; Alama P; Garrido N; Meseguer M; Pellicer A; Remohí J
Reprod Biomed Online; 2009 Oct; 19(4):486-92. PubMed ID: 19909588
[TBL] [Abstract][Full Text] [Related]
19. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles.
Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Ross R
Fertil Steril; 2007 Jul; 88(1):237-9. PubMed ID: 17296193
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.
Kitajima Y; Endo T; Manase K; Nishikawa A; Shibuya M; Kudo R
Fertil Steril; 2004 Mar; 81 Suppl 1():842-9. PubMed ID: 15019818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
